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Condorelli et al. (1) reported the results of a randomized, multicenter 
clinical trial that compared sulodexide with standard therapy in 3,9% 
survivors of acute my~ard%l infarction. First. we were very surprised 
that the control patie& did not receive aspirin, which is obviously vcv 
e&&e in this etting.! Moreover, aspirin treatment was an exclusion 
criteria. In the Discussion section of their report, the authors justify the 
absence of an aspirin-treated arm by the fact that when the trial was 
&ripcJ (in B&l), published reports had not yet shown a “clear 
bcncht from anlithrombtic therapy in terms of survival” (I). There is 
no iqdicatior of the actual trial duration, but WC can infer from the text 
that the trial was not stopped premi~t~r~l~ bccau,X of increasing 
evidence of the beneficial effect of aspirin in post-myocardial infarc- 
lion patientu. Hence, because of the large number of patients random- 
Bed and the relatively few ccntcrs involved, the reader can infer that 
the randomization process was continued even after the results of the 
ISI!% trial (2) were published. If this is true, thun several “control” 
patients did not receive effcctivr treatment because they were used as 
cr,ntrol subjects for a potentially beneficial one. We wonder why the 
Ethktl Committee or the Safety Monitoring Board did not stop the 
trial in view of the important new disclosures of the ISIS-2 invcstiga- 
tars. Second. with regard to the “written informed consent” that the 
patients gave before randomization, we suspect hat the consent form 
was not updated after the disclosure of the ISIS-2 results; otherwise. 
WC do rrclt understand why a patient would choose to enter a trial that 
deliberately denied (to half of the patients) a life-saving treatment. 
In reply to Fresco et al., wc would like to point out the following 
consideratinns. The IPO-V2 trial (I) begin on Mrrch 8, 198s and 
cnde4 on De&umber .3t_l, 1989. The recruitment period Wi\s concluded. 
therefore. on January I, 1989. The results of the ISIS-2 trial were 
published in August I988 (2). Thus, the vast majority of patients in the 
PO-V2 trial had already been enrolled by that time. 
With regard to the remaining patients who entered our study after 
the results of the ISIS-2 trial were made public, the Ethical Committee 
decided that even though the ISIS-2 was an important and well- 
conducted study, pending further confirmation of it< results hy other 
investigators the decision to stop the trial or to add aspirin to both 
arms of the study was not warranted. la retrospect, and in view of tbr 
debate concerning the use of aspirin in the management of post- 
myocardial infarction patients, we consider the decision of the Ethical 
Committee quite appropriate. We hope that these considerations will 
be shared by the readers of the Journal. 
Bancrjcc et al. (1) assert that the relation bctwcen end-systolic stress 
(ESS) and the mcun rate-corrcctrd velocity of shortening (VCF,) is 
nonlincur for any constant contractile state and should not bc used a~ 
an index of contractility. I do not believe that the data reported by 
Banerjcc et al. support this linding. There are also other problems with 
this study. 
Nonlinearity of the ESVCF, relation. WC investigated (2) this 
relation over a wide range of afterload. sampling 6 to IO different levels 
of afterload at a constant contraclilc state in each subject. The 
regression was linear and the slope was similar in dilfcrent subjects by 
linear and nonlinear regression analysis. Banerjcc et al. cite only our 
original investigation (2)” but these tindings have been substantiated in 
numerous subsequent investigations (3-10) in humans and in animals. 
Banerjee et al. propose that this large body of accumulated ata are 
incorrect on the basis of theoretic derivation of the ESS-VCF, relation 
from the V,,;,, index dcscrihcd by Sonnenblick and a flawed analysis of 
their own data. 
Although Banerjee ct al. state that the ESS-VCF, relation is 
derived from V,,,:,,, this is incorrect. The ESS-VCF, relation uses a 
mean normalized velocity. not a Tbak absolute velocity, and assesses 
afterload as end-systolic stress instead of the instantaneous tress at 
the instant of peak velocity. In an elegant series of experiments by Suga 
et al. (3) end-systolic stress has been shown to be the force limiting 
shortening and to hold no constant relation to stress at any point 
earlier in the cardiac cycle. The V,, is an isovolumic phase index, 
whereas ESS VCF, is an ejection phase index. Much 01’ the V,,, curve 
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is obtained by e~tra~o~at~o~ in contrast o the direct mcasurcment of 
SS.VCF, relation. There is no known mathematic or physi&@c 
principle that would predict that the ~~~~~~~~ea~ity of V,,,:,, impI& tha: 
ESS-VCF, is ~o~~iI~ea~. The derivation of the afterload- and prcload- 
~~djusted shortening (S,,l-~r,,,-(r:,l,) and shortening rate (SK,,,- ~rti,,-~r,,,l) 
from the systolic myocardial stitfncss concept 01 
far more relevant. ItI il SClkS Of investigations, VLic and others (5.4.JtI) 
found S,,,--tr,,-~~~.,r~ to be linear, and we ohserved parallel shifts in the 
slope of the regression with increased or decreased contr;ictility. When 
analyzed from 811 appropriate theoretic point of reference, the ESS- 
VCF, rclatinn would indeed Se expected to be linear. 
In their study, Bancrjco et al. (I) collected two data points at each 
contractile state, one at baseline and a single point at higher aftertoad. 
On the basis of these two data points, they speculate that the curve 
connecting them is nonlinear. particularly outside of the observed data 
range. There is 110 valid analysis that permits one to ooncludc thaw ;I 
regression of two points is linear or nonlinear nor to conclude itil~lhillg 
concorning the shape of lhc curve outside the ohscrvcd r:mgc. Invcs- 
IigiltiO~~S performed by us (2,5,“), 10) id by others (3.4.0-S) h;w 
involved multiple 0bSL?lVilti0~lS COllCclCd over il much wider l”illl&!t of 
afterload values, i~lhi~~g critical ~~;m~i~~i~th oI’ tk ~XHCM ial nonlin- 
eilrity of this relation, and none was found. 
~~teruu~m~~ va~ia~~~j~y of the ~~~~VC p ~~~i~~~~~~~~ IdilllC+_T Cl ill. 
describe a “large and signiiicant i~~terauimal variability” of the slope of 
the ESS-VCF, relation hosed on connecting hvo points, a method that 
does not allow an estimate of the goodness of tit or :I statistical 
estimate of the contidencc inter-4 for the slope. When WC and others 
(2-X) ohtained the slope from multiple lcvcls of iifterload over a broad 
range of nftcrhd, WC fouud no statistically significant diltcrencc in the 
slope value between individuals. 
~u~~~~n~~c~ shifts Qf the ESS-VC ~e~~ess~~~~ skqr. The otlscr- 
vation that Icd Bancrjee et al. to speculate that the ESS-VCF, relation 
is nonlinear was the finding that during dohutaminc infusion they 
observed an apparent increase in the slope of the ESS-VCFc relation. 
The correct method of analysis would hc to compare the slope of the 
ESS-VCF, regression for any individual subject at hasclinc with that 
observed during dobutaminc infusion. Bancrjec ct al. cannot perform 
this analysis IltXiWiC they IlilVC insutlicicnt data points for statistical 
analysis and are left with zero degrees of freedom for either the 
regression or the comparison of slopes. 
During low dose infusions of dobutaminc, we observed (2 [Fig. 61) 
a trend toward y,ccpcr $11t still linear) regressions. In our more recent 
work (5,9.10) using midwall analysis, we found that the slope of the 
midwall velocity versus afterload regression does not change with 
altered contractilil;. This apparent difference between midwall and 
endocardial shortening velocity appears related to the finding that 
endocardial shortening overestimates average transmural lihcr short- 
ening (IU). This effect is augmented at higher end-systolic wall 
thicknesses, as seen during hypertrophy and enhanced contractility. 
The point that Sanerjee et al. seem to miss is that we never used 
the slope of the ESS-VCF, relation as an index of contractility; rather, 
we used the position of the relation with respect to the normal range. 
It should be noted that, similar to our findings, they did not find an 
overlap of data ranges between subjects with normal and enhanced 
contractility. 
Investigation af the ESS-VCF, relation at low afterload. Banerjce 
et al. (1) state that “At low afterloads, the curvilinearity of this relation 
becomes more apparent. Previous studies have not investigated the 
relation at low afterload, evaluating contractility only at normal and 
increased (during methoxamine infusion) afterload.” Banerjee et al. 
used exactly the same approach that we did (afterload enhancement 
only for any given contractile state) and therefore did not investigate 
the relation at low afterload for any given contractile state. an 
apreemcnt with our previous findings (2) fhey observed J decrease in,
afterload from baseline levels during dobutamine infusion. This does 
not permit conclusions concerning the behavior of the relation at 
reduced s8*Xrload for a constant contractile state. When the behavior 
of the rokion :I~ reduced afterload but constant contractile state was 
investigated by infuston of nitroprusside (4,8), the relation was ob- 
served to be linear, in Contras, to the speculations of Banerjee et al. 
Thus, it appears that anerjee et al. have been misled by incorrect 
methods of analysis. Further definition of the limitations and short- 
comings of the ESS-VCF, relation as an index of contractility is 
needed, but the report by Bancrjee et al. only undermines that process. 
Dr. Golan grossly misstates our lindings when he states that wc 
concluded “the relaGon between end-systolic stress (ESS) and the 
mean rate-corrected velocity of shortening (VCF;.) . . . should not be 
used as an index for contractility” (1). Conversely, we stated that “the 
